ClinicalTrials.gg

Program

CT204V-CD19 × CD20

A development code.

Its studies are led by AstraZeneca.

Furthest: phase 2, since Nov 6, 20261 company-led study, 1 open or runningNext primary completion: Oct 15, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca11 open or runningphase 2since Nov 6, 2026Nov 6, 2026Oct 15, 2029phase 2 · NCT07932496

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 6, 2026First study: phase 2 study in RecurrenceFirst studyNCT07932496 · 160 planned

Ahead

  1. Oct 15, 2029Primary completion: phase 2 study in RecurrenceNCT07932496

TargetBeta

CD19 →MS4A1 →read by rule
“A Modular, Phase I/II, Open-label, Single-arm, Multicenter, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of CT204V-CD19 × CD20, an In Vivo Lentiviral Vector Gene Therapy Generating Dual Targeting Anti-CD19/CD20 Ch…”study text, by rule · the study

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32
zamtocabtagene autoleucelrulemiltenyi-biomedicine-gmbhphase 28
Autologous Anti-CD19/CD20 CAR-T Cells KITE-363ruleGilead Sciencesphase 23
prizloncabtagene autoleucelruleAbelZetaphase 22
GSK5926371GlaxoSmithKlinephase 22
Allogeneic Anti-CD19/CD20 CAR T-cells AVC-203ruleavencell-therapeutics-incphase 21
HB2198rulehinge-biophase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07932496Recurrence2Not yet recruitingOct 15, 2029160

How it is read

Names in the registry

  • “CT204V-CD19 × CD20”, 1 entry

Codes read as this program: CT204V.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.